BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 30488862)

  • 1. Role of consolidative radiation therapy for patients with mediastinal diffuse large B-cell lymphoma in the rituximab era.
    Sert F; Kamer S; Saydam G; Anacak Y
    J Cancer Res Ther; 2018; 14(6):1397-1402. PubMed ID: 30488862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy.
    Shi Z; Das S; Okwan-Duodu D; Esiashvili N; Flowers C; Chen Z; Wang X; Jiang K; Nastoupil LJ; Khan MK
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):569-77. PubMed ID: 23540349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefit of consolidative radiation therapy for primary bone diffuse large B-cell lymphoma.
    Tao R; Allen PK; Rodriguez A; Shihadeh F; Pinnix CC; Arzu I; Reed VK; Oki Y; Westin JR; Fayad LE; Medeiros LJ; Dabaja B
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):122-9. PubMed ID: 25754633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
    Phan J; Mazloom A; Medeiros LJ; Zreik TG; Wogan C; Shihadeh F; Rodriguez MA; Fayad L; Fowler N; Reed V; Horace P; Dabaja BS
    J Clin Oncol; 2010 Sep; 28(27):4170-6. PubMed ID: 20713859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multi-institutional and case-matched control study on treatment outcomes of consolidative radiotherapy after a full course of R-CHOP compared with R-CHOP alone in Stage I-II diffuse large B-cell lymphoma (KROG 17-02).
    Chung MJ; Cho WK; Oh D; Eom KY; Kim JH; Kim WC; Lee JH
    J Radiat Res; 2019 Oct; 60(5):677-684. PubMed ID: 31251343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real world experience of R-CHOP with or without consolidative radiotherapy vs DA-EPOCH-R in the first-line treatment of primary mediastinal B-cell lymphoma.
    Chan EHL; Koh LP; Lee J; De Mel S; Jeyasekharan A; Liu X; Tang T; Lim ST; Tao M; Quek R; Farid Bin Harunal Ras M; Lee YS; Diong C; Tan D; Kim SJ; Chee YL; Poon LMM
    Cancer Med; 2019 Aug; 8(10):4626-4632. PubMed ID: 31264808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of local recurrence after rituximab-based chemotherapy alone in stage III and IV diffuse large B-cell lymphoma: guiding decisions for consolidative radiation.
    Jegadeesh N; Rajpara R; Esiashvili N; Shi Z; Liu Y; Okwan-Duodu D; Flowers CR; Khan MK
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):107-12. PubMed ID: 25863758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
    Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D
    Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radioimmunotherapy with (131)I-rituximab as consolidation therapy for patients with diffuse large B-cell lymphoma.
    Shin DY; Byun BH; Kim KM; Kang JH; Lim I; Kim BI; Lee SS; Choi CW; Kang HJ; Lim SM
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):825-31. PubMed ID: 27577259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience.
    Savage KJ; Al-Rajhi N; Voss N; Paltiel C; Klasa R; Gascoyne RD; Connors JM
    Ann Oncol; 2006 Jan; 17(1):123-30. PubMed ID: 16236753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Additional survival benefit of involved-lesion radiation therapy after R-CHOP chemotherapy in limited stage diffuse large B-cell lymphoma.
    Kwon J; Kim IH; Kim BH; Kim TM; Heo DS
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):91-8. PubMed ID: 25721091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP.
    Freeman CL; Savage KJ; Villa DR; Scott DW; Srour L; Gerrie AS; Brown MJ; Slack GW; Farinha P; Skinnider B; Morris J; Bénard F; Aquino-Parsons C; Lo A; Pickles T; Wilson DC; Tonseth P; Connors JM; Sehn LH
    Blood; 2021 Feb; 137(7):929-938. PubMed ID: 32871586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Excellent outcomes and lack of prognostic impact of cell of origin for localized diffuse large B-cell lymphoma in the rituximab era.
    Kumar A; Lunning MA; Zhang Z; Migliacci JC; Moskowitz CH; Zelenetz AD
    Br J Haematol; 2015 Dec; 171(5):776-83. PubMed ID: 26456939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Consolidative Radiotherapy after a Complete Response to Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma in the Rituximab Era: Results from a Systematic Review with a Meta-Analysis.
    Hu C; Deng C; Zou W; Zhang G; Wang J
    Acta Haematol; 2015; 134(2):111-8. PubMed ID: 25925586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of radiation therapy in primary breast diffuse large B-cell lymphoma in the Rituximab era: a SEER database analysis.
    Liu PP; Wang KF; Jin JT; Bi XW; Sun P; Wang Y; Yang H; Li ZM; Jiang WQ; Xia Y
    Cancer Med; 2018 May; 7(5):1845-1851. PubMed ID: 29624913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective analysis of primary gastric diffuse large B cell lymphoma in the rituximab era: a multicenter study of 95 patients in Japan.
    Tanaka T; Shimada K; Yamamoto K; Hirooka Y; Niwa Y; Sugiura I; Kitamura K; Kosugi H; Kinoshita T; Goto H; Nakamura S
    Ann Hematol; 2012 Mar; 91(3):383-90. PubMed ID: 21822617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of rituximab and radiotherapy for patients with primary mediastinal large B-cell lymphoma receiving doxorubicin-containing chemotherapy.
    Xu LM; Fang H; Wang WH; Jin J; Wang SL; Liu YP; Song YW; Ren H; Zhou LQ; Li YX
    Leuk Lymphoma; 2013 Aug; 54(8):1684-90. PubMed ID: 23137070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era.
    Bobillo S; Joffe E; Lavery JA; Sermer D; Ghione P; Noy A; Caron PC; Hamilton A; Hamlin PA; Horwitz SM; Kumar A; Matasar MJ; Moskowitz A; Owens CN; Palomba ML; Batlevi CL; Straus D; von Keudell G; Zelenetz AD; Yahalom J; Dogan A; Seshan VE; Younes A
    Blood; 2021 Jan; 137(1):39-48. PubMed ID: 32730585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736.
    Stephens DM; Li H; LeBlanc ML; Puvvada SD; Persky D; Friedberg JW; Smith SM
    J Clin Oncol; 2016 Sep; 34(25):2997-3004. PubMed ID: 27382104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment Selection and Survival Outcomes in Early-Stage Diffuse Large B-Cell Lymphoma: Do We Still Need Consolidative Radiotherapy?
    Vargo JA; Gill BS; Balasubramani GK; Beriwal S
    J Clin Oncol; 2015 Nov; 33(32):3710-7. PubMed ID: 26261253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.